EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia

Xiaoyuan Gong iD, Yuntao Liu, Qiuyun Fang, Runxia Gu iD, Kaiqi Liu iD, Dong Lin, Chunlin Zhou, Guangji Zhang, Benfa Gong iD, Shuning Wei, Yan Li, Shouyun Li und 7 weitere

Blood · 2026

DOI: 10.1182/blood.2026033577 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Blood, 2026. Verfasst von Xiaoyuan Gong und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The B-cell lymphoma 2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome–negative (Ph−) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received venetoclax combined with pediatric-inspired chemotherapy. The primary end point was the rate of measurable residual disease (MRD) negativity by multiparameter flow cytometry (MFC) after induction. The complete remission rate was 91.0%, and 73.0% of responders achieved MFC-MRD negativity, meeting the primary end point. After a median follow-up of 19.3 months, median overall and disease-free survival were not reached; estimated 2-year survival rates were 78.5% and 76.7%, respectively. Propensity score–matched analysis confirmed superior survival compared with historical chemotherapy-only controls. Grade ≥3 adverse events were primarily hematologic toxicities and infections, with an incidence comparable with that of the historical cohort. These results demonstrate that adding venetoclax to pediatric-inspired chemotherapy significantly improves MRD response and survival outcomes in newly diagnosed (ND) Ph− ALL, with a manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT05660473.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicPrecursor Cell Lymphoblastic Leukemia-LymphomaSulfonamidesAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDisease-Free SurvivalNeoplasm, ResidualPhiladelphia ChromosomeProspective StudiesRemission Induction

Substanzen

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Autor:innen und Institutionen

  • National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • Tianjin Institutes of Health Science, Tianjin, China.

ORCID-Profile: Xiaoyuan Gong, Runxia Gu, Kaiqi Liu, Benfa Gong, Ying Wang, Shaowei Qiu, Ying Wang, Yingchang Mi, Hui Wei, Jianxiang Wang

Zitieren

APA

Gong, X., Liu, Y., Fang, Q., Gu, R., Liu, K., Lin, D., Zhou, C., Zhang, G., Gong, B., Wei, S., Li, Y., Li, S., Wang, Y., Qiu, S., Liu, B., Wang, Y., Mi, Y., Wei, H., & Wang, J. (2026). Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood.2026033577

Vancouver

Gong X, Liu Y, Fang Q, Gu R, Liu K, Lin D, et al. Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood. 2026. doi:10.1182/blood.2026033577

BibTeX
@article{Gong2026,
  author = {Gong, Xiaoyuan and Liu, Yuntao and Fang, Qiuyun and Gu, Runxia and Liu, Kaiqi and Lin, Dong and Zhou, Chunlin and Zhang, Guangji and Gong, Benfa and Wei, Shuning and Li, Yan and Li, Shouyun and Wang, Ying and Qiu, Shaowei and Liu, Bingcheng and Wang, Ying and Mi, Yingchang and Wei, Hui and Wang, Jianxiang},
  title = {Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia},
  journal = {Blood},
  year = {2026},
  doi = {10.1182/blood.2026033577}
}
Kostenlos starten →